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ABSTRACT
Purpose:  Lamins A/C, a major component of the nuclear lamina, plays key roles in 
maintaining  nuclear  integrity,  regulation  of  gene  expression,  cell  proliferation  and 
apoptosis.   Reduced lamin A/C expression in cancer has been reported to be a sign of 
poor prognosis. However, its clinical significance in breast cancer remains to be defined. 
This  study aimed to evaluate expression and prognostic  significance of  lamin A/C in 
early-stage breast cancer.
Methods:  Using immunohistochemical  staining of  tissue  microarrays,  expression of 
lamin  A/C was  evaluated  in  a  large  well-characterised  series  of  early-stage  operable 
breast  cancer  (n=938)  obtained  from  Nottingham  Primary  Breast  Carcinoma  Series. 
Association of lamin A/C expression with clinicopathological parameters and outcome 
was evaluated.
Results:  Positive expression rate of lamin A/C in breast cancer was 42.2% (n=398). 
Reduced/loss  of  expression  of  lamin  A/C  was  significantly  associated  with  high 
histological grade (p<0.001), larger tumour size (p=0.004), poor Nottingham Prognostic 
Index (NPI) score (p<0.001),  lymphovascular invasion (p=0.014) and development of 
distant metastasis (p=0.027).  Survival analysis showed that reduced/loss of expression of 
lamin  A/C  was  significantly  associated  with  shorter   breast  cancer  specific 
survival (p=0.008).
Conclusion: This study suggests lamin A/C plays a role in breast cancer and loss of its 
expression is associated with variables of poor prognosis and shorter outcome. 
 Keywords: Breast cancer, Lamin A/C, immunohistochemistry, tissue microarray, 
prognosis. 
INTRODUCTION
Lamins, type V intermediate filament proteins, are the major component of the nuclear 
lamina  [1]  and  are  classified  into  A (lamin  A and  C)  and  B  types.  Lamin  A/C  are 
implicated in a multitude of functions within the cell [2] including binding to chromatin, 
maintaining  nuclear  integrity,  apoptosis  and  regulating  gene  expression  and  cell 
proliferation.  Lamin  proteins  are  involved  in  regulating  cell  proliferation  through 
different mechanisms including oxidative stress and reactive oxygen species signalling 
pathways and modulation of phosphoinositide 3-kinase signaling pathway [3, 4]. A-type 
lamins  also  participate  in  many  other  cell  functions  through  binding  to  a  myriad  of 
nuclear, signal transduction and gene regulatory proteins [5, 6].
Lamins are synthesized throughout the cell cycle and the lamina is depolymerized and re-
polymerized during mitotic prophase and telophase respectively [7, 8]. Cells deficient in 
LMNA gene  exhibit  enhanced  proliferation,  impaired  cellular  migration  and  nuclear 
orientation  [9,  10].  Conversely,  in  vivo  lamin  A/C  over-expression  inhibits  cell 
proliferation [11]. Mutations in the LMNA gene cause different degenerative disorders 
collectively called laminopathies which are associated with a wide range of  heritable 
diseases including muscular dystrophies and premature ageing [12].
Nuclear changes are hallmarks of cancer and diagnosis of malignant transformation in 
pathological specimens depends on the presence of characteristic alterations in nuclear 
shape and heterochromatin and also used in evaluation of grade and hence prognosis in 
breast cancer [13, 14]. As lamins are thought to be a principal determinant of nuclear 
shape  and  architecture,  it  is  hypothesised  that  they  are  responsible  for  the  structural 
changes observed in cancer cells. Moreover, α-helical rod domain of A-type lamins bind 
to chromatin both directly and indirectly through other proteins e.g. Emerin and lamin- 
associated protein 2 (LAP2) [15–17]. 
Mechanisms underlying the role of lamin in cancer have been speculated and this has led 
to the conclusion that A-type lamins contribute to tumorigenesis and progression. A-type 
lamin  in  fibroblasts  have  important  interactions  with  nuclear  proteins,  emerin  and 
LAP2α, influencing the activity of oncogene β-catenin and Retinoblastoma protein (pRb) 
growth regulators [18].
A-type Lamins are not only expressed in terminally differentiated mammalian cells; but 
are  also  found  in  embryonic  stem  cells  but  at  low  amounts  [19,  20].  Lamins  are 
differentially expressed in normal and cancer tissues. For instance both lamin A and C are 
highly expressed in basal and squamous cell carcinoma but lamin C is expressed in all 
layers of the normal epidermis while lamin A expression was absent in the normal basal 
layers [21]. In contrast,  decreased expression of lamin A/C is seen in small cell  lung 
cancer (SCLC) but not in non-SCLC in which it  was also aberrantly localised to the 
cytoplasm [22, 23]. Moreover, reduced expression of lamin A/C has also been reported in 
adenocarcinoma  of  stomach,  colon,  and  oesophageal  carcinoma  [24].  Reduced  or 
negative lamin A/C expression is associated with poor prognosis in a number of cancers 
including gastric carcinoma, lymphomas, lung, colon and breast cancer [23, 25–29].
Some studies  of  lamin A/C expression in  breast  cancer  have also reported decreased 
expression [24, 28–31]. However, most of these studies included small sample sizes and 
with scarce comment of the clinical outcome.
To  assess  the  prognostic  effect  of  lamin  A/C  in  breast  cancer  and  association  with 
different  clinical  parameters,  we  investigated  its  expression  in  a  large  and  well-
characterised  series  of  early-stage  breast  carcinoma  with  a  long-term  follow-up  and 
correlated this with clinicopathological variables and outcome. 
MATERIALS AND METHODS 
Patients and tissue specimens
A total of 938 cases of operable invasive breast carcinoma obtained from Nottingham 
Tenovus Primary Breast Carcinoma Series were investigated. This is a well characterised 
series of primary breast carcinoma with long term follow-up that were routinely assessed 
for  tumour  type,  tumour  size,  histological  grade,  vascular  invasion  and  Nottingham 
Prognostic  Index (NPI).  The  median  follow up time was  146 months  (range  1-244). 
Information on local  and regional  recurrence,  presence of  distance metastasis,  lymph 
node status, survival and therapy were collected on a prospective basis. The patients were 
treated in a uniform way and the series has previously been used to study a wide range of 
biomarkers  including  oestrogen  receptor  (ER),  progesterone  receptor  (PgR),  HER2, 
EGFR, p53 and E-cadherin [32]. Breast cancer specific survival (BCSS) was defined as 
the length of time (in months) from the date of the primary surgery to the time of breast 
cancer-related death, and disease free interval (DFI) was defined as the length of time (in 
months)  from the  date  of  the  primary  surgery  to  the  first  locoregional  recurrence  or 
distant metastasis. NPI is derived as follows: NPI=0.2 x pathological tumour size (cm) + 
histological grade (1-3) + lymph node stage.  The NPI divides patients into three sub-
groups;  good  (≤  3.4),  moderate  (3.41-5.4)  and  poor  (>5.4)  prognostic  groups  [33]. 
Patients were managed according to their hormonal status and NPI score; those with an 
NPI score ≤  3.4 received no adjuvant  therapy,  those with a  NPI score >3.4 received 
Tamoxifen if ER positive (± Zoladex if pre-menopausal) or classical cyclophosphamide, 
methotrexate and 5-fluorouracil if ER negative and fit enough to tolerate chemotherapy 
[34].  Patient details and clinicopathological characteristics are listed in Table 1. 
Ethical approval for this study was granted by Nottingham Research Ethics committee 2 
under the title of “Development of a molecular genetic classification of breast cancer”
Immunohistochemistry 
Breast cancer tissue microarrays (TMA) were prepared as previously described [34]. The 
monoclonal antibody to lamin A/C (Cell signalling Mouse monoclonal antibody, #2032) 
was  used  for  immunohistochemical  detection.  After  deparaffinisation  in  xylene  and 
rehydration through graded alcohol, sections were immersed in 0.1M citrate buffer pH 
6.0 and microwaved for 20 minutes in order to retrieve antigenicity.  Once complete, 
slides  were  cooled  and  rinsed  with  Tris  Buffered  Saline  (TBS)  pH 7.6.  Endogenous 
peroxidase activity was inhibited using peroxidase block (Dako Real peroxidise blocking 
solution,  S2023) for 5 minutes followed by TBS rinse.  Sections were incubated with 
Ultra  V  block  (ThermoScientific  TA-125-UB)  to  block  non-specific  staining  by  the 
primary antibody for 5 minutes at room temperature. The antibody was optimally diluted 
to 1:20 and incubated for 30 minutes at room temperature.   After washing with TBS, all 
sections  were  incubated  with  a  secondary  antibody  (dextran  coupled  peroxidase 
molecules and goat anti-mouse/rabbit immunoglobulin; Dako REAL™ EnVision™/HRP, 
Rabbit/Mouse bottle A, K5007) for 30 min. Sections were washed in TBS and incubated 
with freshly prepared 3’3-diaminobenzidine (Dako Envision Kit, Bottle B and C, K5007) 
for  5  minutes  and  repeated  once.  After  rinsing  in  TBS  three  times,  sections  were 
counterstained with haematoxylin (Dako Real Automation Haematoxylin, S3301) for 6 
min.  After  washing in  tap water,  the  sections  were  dehydrated in  ethanol,  cleared in 
xylene and mounted with DPX (BDH, Poole, UK). A formalin-fixed paraffin embedded 
tissue section from a primary ductal carcinoma was used as a positive control for lamin 
A/C staining. 
Evaluation of immunohistochemical staining
Immunoreactivity of Lamin A/C in the TMA cores was evaluated semi-quantitatively by 
assessing both percentage of cells stained and intensity of staining. Nuclear staining of 
the TMA cores was measured using the modified Histochemical-score (H-Score) with a 
range from 0 to 300. H-score was calculated as the sum of the percentage of cells with 
weak, moderate and strong staining. The staining intensity was scored as 0 (no staining), 
1 (weak staining), 2 (moderate staining), and 3 (strong staining). Only staining of the 
invasive malignant cells within the tissue cores was considered. TMAs were manually 
assessed  using  high  resolution  digital  images  (NanoZoomer;  Hamamatsu  Photonics, 
Welwyn Garden City, UK), at X20 magnification, using a web-based interface (Distiller; 
Slidepath Ltd, Dublin, Ireland). All samples were scored by one observer (IA) and each 
core was scored twice and the average taken. The intraobserver agreement was good as 
suggested by Cohen’s  kappa value κ  =  0.80 and a  95% confidence interval  between 
0.93-0.68.
Statistical Analysis 
Statistical  analysis  was  performed  using  SPSS  v18  statistical  software.  Chi-squared 
analyses  were  used  for  correlations  between  Lamin  A/C  expression  and 
clinicopathological  parameters,  steroid  receptors  and  biomarkers.  Possible  correlation 
between Lamin A/C expression levels and BCSS and disease free interval was examined 
using Kaplan–Meier curves and differences between the curves were analysed using the 
log-rank test. Cox regression models were used for multivariate analysis to test the effect 
of Lamin A/C expression and clinicopathological parameters on disease-free survival and 
BCSS  as  well  as  its  statistical  independence.   A P-value  of  <0.05  was  considered 
statistically significant. 
RESULTS
Immunohistochemical examination revealed positive staining of lamin A/C localised to 
the nuclear envelope of invasive breast cancer cells (Figure 1).  Stromal fibroblasts and 
vascular endothelial cells showed positive staining for nuclear lamin A/C which provided 
a positive control for expression. A total of 96% (900/938) of cases demonstrated varying 
degrees of nuclear staining to lamin A/C in the tumour cells while 4% (38/938) showed 
complete absence of nuclear staining. Data were categorised into two groups according to 
frequency distributions and Kaplan- Meier curves of the effect on BCSS and cut-off was 
selected using X-tile software [35].  Low/absent nuclear expression was defined as H-
score ≤ 150 and high nuclear expression as H-score >150. High expression of lamin A/C 
was observed in 398/938 (42.3%) tumours while negative expression rate of lamin A/C 
was 540/938 (57.7%).
Correlation of lamin A/C expression with clinicopathological parameters
Reduced/absent lamin A/C expression was associated with high mitotic frequency and 
nuclear  pleomorphism  (p=<0.001),  high  grade  tumours  (p<0.001),  larger  tumours 
(p=0.004), vascular invasion (p=0.014), poor NPI score (p<0.001) and presence of distant 
metastases (p = 0.027) (Tables 2 and 3). Negative expression of lamin A/C was associated 
with invasive ductal/no special  type and atypical  medullary histological  tumour types 
(p=0.002). Lamin A/C expression was not associated with age at diagnosis, nodal stage, 
or loco-regional recurrence.
Association of lamin A/C with biomarkers expression
Relationships between lamin A/C and biomarkers are summarised in Table 4. Tumours 
with high expression for lamin A/C was significantly associated with ER (p=0.002) and 
PgR positivity (p=0.001).  On the other hand, HER2 positive tumours had a negative 
association with lamin A/C expression (p=0.005). Low lamin A/C immunoreactivity was 
further correlated with triple negative status (p=0.026). Low Lamin A/C expression also 
showed  significant  association  with  high  p53  expression  (p=0.001).  There  was  no 
correlation between lamin A/C with either E-cadherin or Ki67 expression. 
Association of lamin A/C with patient outcome
Tumours  with reduced/absent  Lamin A/C expression showed significantly shorter BCSS 
compared with those showing high expression for the biomarker (p=0.008) (Figure 2). 
On the other hand low/absent expression of lamin A/C was associated with a trend for 
shorter DFI (distant metastasis (p=0.057) but there was no association with loco-regional 
recurrence  (p=0.360)  (Figures  3  & 4).  High Lamin A/C expression  was  significantly 
associated with BCSS in ER positive (p=0.026) but not ER negative patients (p=0.442). 
In multivariate analysis, expression of lamin A/C was not independent of tumour grade, 
size and stage for both BCSS and DFI (Table 5).
DISCUSSION
Lamins have been implicated in a variety of diseases and cancers and reported as having 
prognostic significance. In breast cancer, a study of lamin A/C expression on 56 invasive 
ductal  carcinoma  in  tissue  microarrays  showed  that  lamin  A/C  immunostaining  was 
completely absent in 21/56 (38%) of cases [30].  Our study showed that the majority of 
the breast cancer tissues demonstrated expression of lamin A/C; however, strong nuclear 
staining of invasive breast carcinoma cells was also evident in some cancer tissues.  
In addition, we observed a correlation between high lamin A/C expression and breast 
cancer  clinico-pathological  parameters  associated  with  a  good  prognosis.  Therefore 
breast tumours negative for lamin A/C expression were more likely to have an aggressive 
phenotype. Many poorly differentiated tumours from various sites have been described to 
show reduced lamin A/C expression [24, 26, 28], which supports our findings whereas 
low lamin A/C was associated with the poor prognostic NPI group, HER2 positive and 
triple  negative  tumours,  vascular  invasion,  larger  tumours  and  poor  differentiation 
implying  that  measurement  of  lamin  A/C  could  provide   an  additional  prognostic 
information.
However,  multivariate  analysis  showed  that  lamin  A/C  was  not  prognostically 
independent from tumour size, tumour grade and nodal stage. Two previous studies on 
lamin A/C in breast cancer demonstrated that patients with tumour cells down-regulating 
Lamin A/C had a poorer prognosis than those expressing the gene. However compared 
with our study, these studies had a much smaller sample size (n=115 and =73), shorter 
follow-up time and few clinicopathological criteria [28, 29]. 
Studies of lamin A/C in primary gastric carcinoma has also shown similar results to our 
findings,  suggesting  that  tumour  cells  with  low  lamin  A/C  expression  had  a  poor 
prognosis  and  this  was  also  an  independent  prognostic  factor  [26].  It  has  also  been 
demonstrated that loss of lamin A/C expression correlated with decreased overall survival 
in nodal diffuse large B-cell lymphoma [36].  
Different  mechanisms has been proposed for loss of lamin A/C expression in cancer. 
LMNA gene silencing by CpG island promoter hypermethylation has led to inactivation 
of  the  gene  and  loss  of  lamin  A/C  mRNA and  protein  expression  in  hematologic 
malignancies [36].  In normal cells, CpG islands are not subject to methylation at any 
stage of cell cycle and they permit the expression of that particular gene if the appropriate 
transcription factors are present and the chromatin is available to them. However, CpG 
islands of tumour suppressor genes, in tumour cells, become hypermethylated [37, 38]. 
Gene  silencing  caused  by  methylation  is  a  common  and  early  event  in  breast 
tumorigenesis  [39–41].  Furthermore,  methylation  of  the  tumour  suppressor  genes  in 
breast cancer is linked with poor prognostic indicators and hormonal receptor status [42–
46].  Lamin A/C might thus serve as a tumour suppressor based on these findings [47]. 
There are reports on hypermethylation of the regulatory regions of many breast tumour-
related genes such as p53, Cyclin D1, ER ,  PgR, E-cadherin,  H-cadherin,  Caspase-8, 
BRCA1, HOXA7, RASSF1 and HOXB13 further supporting the suggestion of lamin A/C 
hypermethylation [39, 48–50]. 
To determine whether lamin A/C expression was correlated with cellular proliferation, we 
analysed co-expression of lamin A/C and Ki67 where the majority of highly proliferative 
tumours  showed  low  expression  for  lamin  A/C;  however,  the  association  was  not 
statistically significant. In a study of basal cell carcinoma, reduced expression of lamin A 
was shown in most hyperproliferative tumours expressing Ki67. It seems that decreased 
A-type lamin expression is inversely proportional to proliferation in cancer cells.
Lamins  are  required  for  growth  of  the  nuclear  envelope  and  for  increase  of  nuclear 
volume during the cell cycle and progression into S phase is dependent on the possession 
of a certain nuclear volume [51].  In addition, the down-regulation of lamins leads to 
abnormal condensation of chromatin. This may explain the high association of lamin A/C 
negative expression with high grade mitosis. 
 This study suggests lamin A/C expression as a potential prognostic biomarker for early 
operable invasive breast cancer. Our findings indicate that lamin A/C expressing tumours 
are  associated  with  better  breast  cancer  specific  survival  and  reduced  lamin  A/C 
expression is associated with more aggressive tumours. Further analysis of lamin A and 
lamin C expression would be useful to investigate if there is differential expression and 
effect on clinical outcome comparing with normal breast samples. DNA methylation and 
gene silencing studies of LMNA gene is interesting to study the role of lamin A/C in 
breast tumourigenesis.
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Table 1 clinico-pathological criteria of study patients
Clinico-pathological	parameter No.	of	pa4ents	(%)
Age ≤ 50 years 
Age ≥ 50 years
309 (32.9) 
629 (67)
Local recurrence 
Distant metastasis
392 (41.8) 
302  (32.2)
BCSS: 
Lymph node negaIve cohort 
Lymph node posiIve cohort
123 (62.8) 
145 (28.6)
Tumour size < 1.5 cm 
Tumour size > 1.5 cm
198 (21) 
733 (78)
Deﬁnite vascular invasion 312 (33)
Received Endocrine therapy 
Received Chemotherapy
300 (32) 
178 (19)
Grade 1 
Grade 2 
Grade 3
140 (14.9) 
269 (28.7) 
522 (55.7%)
NPI score: 
Good prognosis 
Moderate prognosis 
Poor Prognosis
229 (24.4) 
503 (53.6) 
197 (21)
Table 2 Correlation of Lamin A/C expression with clinico-pathological parameters
Lamin	A/C
         Parameter
Nega4ve																																												
		n=540	(%)																																																							
Posi4ve
	n= 398(%)
p-Value
Grade
1 60(11.2) 81(20)
<0.0012 134(25) 137(34.9)
3 346(64.3) 176(44.8)
Total 540 394
LN	Stage
1 311(57.9) 245(62.2)
0.3542 173(32.2) 118(30)
3 53(10) 31(7.9)
Total 538 393
Tumour	size
< 1.5 cm 98(18.2) 100(25.4)
0.004
≥ 1.5 cm 440(81.8) 293(74.6)
Total 538 393
Distant	metastases
No 352(65.3) 278(70.7)
Deﬁnite 187(34.7) 115(29.3) 0.027
Total 539 393
NoOngham	Prognos4c	Index
Good 107(20 122(31)
<0.001Moderate 294(54.7) 209(53.3)
Poor 136(25.3) 61(15.6)
Total 537 392
Tubules
1 21(4) 26(6.9)
2 150(28.5) 142(37.6) 0.001
3 355(67.5) 210(55.6)
Total 526 378
Pleomorphism
1 3(0.6) 8(2.1)
2 154(29.3) 157(41.8) <0.001
3 369(70.2) 211(56)
Total 526 376
Mitosis
1 130(24.7) 144(38)
2 84(16) 82(21.7) <0.001
3 312(59.3) 152(40.2)
Total 526 378
Vascular	Invasion
NegaIve 337(63) 279(70.8)
0.014
Probable 197(36.9) 115(29.2)
Total 534 394
Lamin	A/C
Table 3 Association of lamin A/C expression in breast cancer with histological type 
Tumour	type
Nega4ve	
	(	%)
Posi4ve		
(%)
Invasive	Ductal/No	Special	Type 367(67.6) 215(54.0)
Tubular	Mixed 72(13.3) 79(19.8)
Atypical	Medullary 21(3.9) 5(1.3)
Classical	Lobular 21(3.9) 21(5.3)
Lobular	Mixed 10(1.9) 17(4.3)
Mixed	NST	And		Lobular 15(2.8) 16(4)
Tubular 11(2) 13(3.3)
Mixed	NST	And	A	Special	Type 6(1.1) 7(1.8)
Mucinous 4(0.7) 2(0.5)
Typical	Medullary 1(0.2) 2(0.5)
Solid	Lobular 1(0.2) 1(0.3)
Tubulo-lobular 0 2(0.5)
Invasive	Papillary 2(0.4) 1(0.3)
Miscellaneous		types 10(1.9) 16(4.0)
Total 540 398
																																										P=	0.002
Table 4 The relationship between Lamin A/C expression,  hormonal  receptors and other 
tumour markers expression
Lamin	A/C
Pa4ents Nega4ve	(%) Posi4ve	(%) p	value
ER NegaIve 175(33.3) 88(22.8)
0.002
PosiIve 353(67.0) 299(77.0)
Total 528 387
PgR NegaIve 246(47.2) 134(35.4)
0.001
PosiIve 275(53.0) 244(64.5)
Table  5  Cox  proportional  hazards  analysis  for  predictors  of  breast  cancer  specific  survival 
(BCSS) and disease-free survival (model including lamin A/C expression)
Total 521 378
HER2 NegaIve 442(83) 346(89.5)
0.005
PosiIve 92(17.0) 41(10.5)
Total 534 387
Triple	nega4ve No 412(76) 329(82.5)
Yes 116(21.5) 58(15) 0.026
Total 528 387
ER-PgR	status Both Absent 166(32.3) 78(21)
ER absent 6(1.16) 6(1.6)
Both posiIve 267(52) 237(64) 0.002
ER only 74(14.4) 50(13.5)
Total 513 370
p53 NegaIve 319(67) 268(77.2)
PosiIve 157(33) 79(22.8) 0.001
Total 476 347
Ki67 NegaIve 139(34.3) 121(38.8)
PosiIve 266(65.7) 191(61.2) 0.218
Total 405 312
E-cadherin NegaIve 75(15.7) 50(14.4)
PosiIve 404(84.3) 298(85.6) 0.609
Total 
479 348
Breast cancer specific survival D i s e a s e - f re e  s u r v i v a l 
(recurrence)
Variable Hazard 
ratio
p-value 95% CI H a z a r d 
ratio
p-value 95% CI
T u m o u r 
size
2.153 <0.001 1.408-3.2
90
1.475 0.008 1.105-1.
967
T u m o u r 
stage
1.750 <0.001 1.480-2.0
68
1.651 <0.001 1.424-1.
914
T u m o u r 
grade
1.965 <0.001 1.584-2.4
37
1.271 0.002 1.092-1.
479
Lamin A/C 0.876 0.304 0.680-1.1
28
0.988 0.905 0.803-1.
214
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Fig. 2
Fig. 3
Fig. 4
Figure Legends
Fig. 1 Photograph showing positive  lamin A/C nuclear  staining in  breast  determined 
using immunohistochemistry. 15x magnification 
Fig. 2 Lamin A/C expression in relation to BCSS in breast tumours
Fig. 3 Lamin A/C expression in relation to DFI (metastasis) in breast tumours
Fig. 4 Lamin A/C expression in relation to DFI (Locoregional Recurrence) in breast tumours
